Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anisodine Hydrobromide in Acute Ischemic Stroke Undergoing Endovascular Treatment
NCT07800572Phase 2Recruiting
- Sponsor
- Capital Medical University
- Start
- Sep 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ischemic stroke comparing Anisodine Hydrobromide Group with Anisodine Hydrobromide placebo (2 arms). Primary endpoint: Cerebral Infarct Volume at Day 8. Started Sep 2026; status: recruiting.
02
Drugs
anisodine
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07800572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07800572.